Cargando…

The plasma peptides of Alzheimer’s disease

BACKGROUND: A practical strategy to discover proteins specific to Alzheimer’s dementia (AD) may be to compare the plasma peptides and proteins from patients with dementia to normal controls and patients with neurological conditions like multiple sclerosis or other diseases. The aim was a proof of pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Florentinus-Mefailoski, Angelique, Bowden, Peter, Scheltens, Philip, Killestein, Joep, Teunissen, Charlotte, Marshall, John G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240224/ https://www.ncbi.nlm.nih.gov/pubmed/34182925 http://dx.doi.org/10.1186/s12014-021-09320-2

Ejemplares similares

Random and independent sampling of endogenous tryptic peptides from normal human EDTA plasma by liquid chromatography micro electrospray ionization and tandem mass spectrometry
por: Dufresne, Jaimie, et al.
Publicado: (2017)

The proteins cleaved by endogenous tryptic proteases in normal EDTA plasma by C18 collection of peptides for liquid chromatography micro electrospray ionization and tandem mass spectrometry
por: Dufresne, Jaimie, et al.
Publicado: (2017)

The plasma peptides of ovarian cancer
por: Dufresne, Jaimie, et al.
Publicado: (2018)

The plasma peptides of breast versus ovarian cancer
por: Dufresne, Jaimie, et al.
Publicado: (2019)

Freeze-dried plasma proteins are stable at room temperature for at least 1 year
por: Dufresne, Jaimie, et al.
Publicado: (2017)

The plasma peptidome
por: Dufresne, Jaimie, et al.
Publicado: (2018)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

The plasma peptides of sepsis
por: Thavarajah, Thanusi, et al.
Publicado: (2020)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
por: Prins, Samantha, et al.
Publicado: (2022)

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Thijssen, Elisabeth H., et al.
Publicado: (2021)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020)

Imaging in Alzheimer's disease
por: Scheltens, Philip
Publicado: (2009)

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease
por: Skillbäck, Tobias, et al.
Publicado: (2017)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

gMS-Classifier1 does not predict disability progression in multiple sclerosis
por: van Rossum, Johannis A, et al.
Publicado: (2018)

The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease
por: Jochemsen, Hadassa M, et al.
Publicado: (2014)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
por: Vos, Stephanie J. B., et al.
Publicado: (2014)

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
por: den Haan, Jurre, et al.
Publicado: (2019)

Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia
por: Chakraborty, Ananya, et al.
Publicado: (2018)

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients
por: Sestito, Claudia, et al.
Publicado: (2018)

Heterogeneity of Alzheimer’s disease: consequence for drug trials?
por: Devi, Gayatri, et al.
Publicado: (2018)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6t3eks1q37h85gi2jq5l8dh5c0